
There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins Rough conclusion from #UromigosLive : 👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden 👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK 👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc 👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors. 👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD 👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky 👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1 @uromigos encourage the panel, participants or wider audience to comment or correct @OncoAlert x.com/i/broadcasts/2XybkVKqb…


























